If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.
Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d